Our results of AG attenuating the phosphorylation of Tau, a clinical indicator of neurodegeneration and is clinically associated with AD, proved that the natural broad-spectrum compound could not only attenuate inflammation but could also decrease the accumulation of phosphorylated Tau via microglial deactivation. This evidence concerns the gene MAPT and Alzheimer disease.